Disease · MONDO_0100233

long COVID-19

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. long COVID-19. Diseases, record MONDO_0100233. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0100233

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: long COVID-19; Open Targets
Open Targets ID: MONDO_0100233; Open Targets
Other names: PASC, long haul COVID-19, post-acute sequelae of COVID-19, post-acute sequelae of SARS-CoV-2 infection, sequelae of COVID-19; Open Targets
Disease Ontology: DOID:0080848; Disease Ontology
MeSH: D000094024; MeSH
NCI Thesaurus: C179263; NCI Thesaurus
Highest stage of its drugs: Phase 2/3, for 6 of its 30 drugs, from ClinicalTrials.gov; Open Targets

Drugs30

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
ATORVASTATIN	CHEMBL1487	Small molecule	Phase 2/3	ClinicalTrials.gov	1	1	1	Drugs and targets
FLUVOXAMINE	CHEMBL814	Small molecule	Phase 2/3	ClinicalTrials.gov	1	1	1	Drugs and targets
IBUDILAST	CHEMBL19449	Small molecule	Phase 2/3	ClinicalTrials.gov	1	1	1	Drugs and targets
MARAVIROC	CHEMBL256907	Small molecule	Phase 2/3	ClinicalTrials.gov	1	1	1	Drugs and targets
PENTOXIFYLLINE	CHEMBL628	Small molecule	Phase 2/3	ClinicalTrials.gov	1	1	1	Drugs and targets
TAURINE	CHEMBL239243	Small molecule	Phase 2/3	ClinicalTrials.gov	1	1	1	Drugs and targets
NIRMATRELVIR	CHEMBL4802135	Small molecule	Phase 2	ClinicalTrials.gov	4	4	4	Drugs and targets
RITONAVIR	CHEMBL163	Small molecule	Phase 2	ClinicalTrials.gov	3	3	3	Drugs and targets
MODAFINIL	CHEMBL1373	Small molecule	Phase 2	ClinicalTrials.gov	2	2	2	Drugs and targets
SOLRIAMFETOL	CHEMBL4297620	Small molecule	Phase 2	ClinicalTrials.gov	2	2	2	Drugs and targets

1 to 10 of 30

See all 30 drugs

Targets46

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
HTR2A	5-hydroxytryptamine receptor 2A	2	Serotonin 2a (5-HT2a) receptor antagonist	Phase 2	https://conductscience.org/library/genes/3356	Drugs and targets
HTR2C	5-hydroxytryptamine receptor 2C	2	Serotonin 2c (5-HT2c) receptor antagonist	Phase 2	https://conductscience.org/library/genes/3358	Drugs and targets
NR3C1	Glucocorticoid receptor	2	Glucocorticoid receptor agonist	Unknown	https://conductscience.org/library/genes/2908	Drugs and targets
PDE10A	3',5'-cyclic phosphodiesterase	2	3',5'-cyclic phosphodiesterase inhibitor; Phosphodiesterase 10A inhibitor	Phase 2/3	https://conductscience.org/library/genes/10846	Drugs and targets
PDE3A	3',5'-cyclic phosphodiesterase	2	3',5'-cyclic phosphodiesterase inhibitor; Phosphodiesterase 3A inhibitor	Phase 2/3	https://conductscience.org/library/genes/5139	Drugs and targets
PDE4A	3',5'-cyclic phosphodiesterase	2	3',5'-cyclic phosphodiesterase inhibitor; Phosphodiesterase 4 inhibitor	Phase 2/3	https://conductscience.org/library/genes/5141	Drugs and targets
PDE4B	3',5'-cyclic phosphodiesterase	2	3',5'-cyclic phosphodiesterase inhibitor; Phosphodiesterase 4 inhibitor	Phase 2/3	https://conductscience.org/library/genes/5142	Drugs and targets
PDE4C	3',5'-cyclic phosphodiesterase	2	3',5'-cyclic phosphodiesterase inhibitor; Phosphodiesterase 4 inhibitor	Phase 2/3	https://conductscience.org/library/genes/5143	Drugs and targets
PDE4D	3',5'-cyclic phosphodiesterase	2	3',5'-cyclic phosphodiesterase inhibitor; Phosphodiesterase 4 inhibitor	Phase 2/3	https://conductscience.org/library/genes/5144	Drugs and targets
PDE5A	3',5'-cyclic phosphodiesterase	2	3',5'-cyclic phosphodiesterase inhibitor; Phosphodiesterase 5A inhibitor	Phase 2/3	https://conductscience.org/library/genes/8654	Drugs and targets

1 to 10 of 46

See all 46 targets

Trials19

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 1 more is not shown, since the checks do not confirm it.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT05595369	RECOVER-VITAL: Platform Protocol to Measure the Effects of Antiviral Therapies on Long COVID Symptoms	Phase 2	963	2025-12-02	Long COVID, Long Covid19	NIRMATRELVIR	Its record names the disease	ClinicalTrials.gov
NCT05576662	Paxlovid for Treatment of Long Covid	Phase 2	168	2024-09-25	Post-acute Sequelae of SARS-CoV-2 Infection, Long COVID	NIRMATRELVIR, RITONAVIR	Its record names the disease	ClinicalTrials.gov
NCT05472090	A Phase 2 Study to Evaluate the Efficacy and Safety of TNX-102 SL in Patients With Multi-Site Pain Associated With Post-Acute Sequelae of SARS-CoV-2 Infection	Phase 2	63	2024-11-26	Post-Acute Sequelae of SARS-CoV-2 (PASC) Infection, COVID-19, Long COVID, Long Haul COVID	CYCLOBENZAPRINE, CYCLOBENZAPRINE HYDROCHLORIDE	Its record names the disease	ClinicalTrials.gov
NCT05965726	RECOVER-VITAL: Platform Protocol, Appendix to Measure the Effects of Paxlovid on Long COVID Symptoms	Phase 2	964		Long COVID-19, Long COVID	NIRMATRELVIR, RITONAVIR	Its record names the disease	ClinicalTrials.gov
NCT06404086	RECOVER-SLEEP: Platform Protocol	Phase 2	830		Long COVID, Long COVID-19, Hypersomnia, Sleep Disturbance	MELATONIN, MODAFINIL, SOLRIAMFETOL	Its record names the disease	ClinicalTrials.gov
NCT06597682	Evaluating Immunomodulatory Interventions in Post-Acute Sequelae of SARS-CoV-2 InfEction	Not applicable	632		Post-acute Sequelae of SARS-COV-2 Infection	BUDESONIDE, FORMOTEROL, MONTELUKAST, PREDNISONE, UBIDECARENONE	Its record names the disease	ClinicalTrials.gov
NCT05513560	RECLAIM: Recovering From COVID-19 Lingering Symptoms Adaptive Integrative Medicine	Phase 2/3	460		Long COVID, Post COVID Condition, Post Acute Sequelae of COVID-19	IBUDILAST, PENTOXIFYLLINE	Its record names the disease	ClinicalTrials.gov
NCT06404099	RECOVER-SLEEP: Platform Protocol, Appendix_A (Hypersomnia)	Phase 2	361		Long COVID, Long COVID-19, Hypersomnia	MODAFINIL, SOLRIAMFETOL	Its record names the disease	ClinicalTrials.gov
NCT06721949	Taurine Supplementation in Long COVID	Phase 2/3	300		Long COVID	TAURINE	Its record names the disease	ClinicalTrials.gov
NCT06974084	A Multi-Center, Individually-Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Superiority Trial to Evaluate the Efficacy of the Combination of Maraviroc and Atorvastatin for the Treatment of Subjects With Long COVID	Phase 2/3	252		Long COVID	ATORVASTATIN, MARAVIROC	Its record names the disease	ClinicalTrials.gov

1 to 10 of 19

See all 19 trials

Comparisons in its trials6

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial	Source
Nirmatrelvir Plus Ritonavir vs Placebo Plus Ritonavir: Number of Participants With Overall Alleviation for 2 Weeks	7 of 102	5 of 53	155	NCT05576662	Trial comparisons
Nirmatrelvir Plus Ritonavir vs Placebo Plus Ritonavir: deaths from any cause	0 of 102	0 of 53	155	NCT05576662	Trial comparisons
Nirmatrelvir Plus Ritonavir vs Placebo Plus Ritonavir: Number of Participants Reporting Relief of at Least One Core Symptom for 2 Weeks	33 of 102	22 of 53	155	NCT05576662	Trial comparisons
Nirmatrelvir Plus Ritonavir vs Placebo Plus Ritonavir: serious adverse events	3 of 102	1 of 53	155	NCT05576662	Trial comparisons
TNX-102 SL Tablet, 5.6 mg vs Placebo SL Tablet: deaths from any cause	0 of 32	0 of 31	63	NCT05472090	Trial comparisons
TNX-102 SL Tablet, 5.6 mg vs Placebo SL Tablet: serious adverse events	0 of 32	0 of 31	63	NCT05472090	Trial comparisons

Papers from its trials4

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
40810942	RESULT	1	PubMed
38848477	RESULT	1	PubMed
42673984	DERIVED	1	PubMed
40188838	DERIVED	1	PubMed

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0100233

GET https://conductscience.org/api/diseases/v1/MONDO_0100233/drugs?page=2

API reference For AI assistants